Sarita D Boyd Frank Maldarelli Irini Sereti G Laissa Ouedraogo Catherine A Rehm Valerie Boltz Diana Shoemaker Alice K Pau
10.3851/IMP1749
Antivir Ther
2011;16(2):257-61.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/21447876/
Drug Resistance, Viral / genetics HIV Infections / transmission HIV Integrase Inhibitors / pharmacology HIV-1 / drug effects Pyrrolidinones / pharmacology
Drug Resistance, Viral / genetics HIV Infections / transmission HIV Integrase Inhibitors / pharmacology HIV-1 / drug effects Pyrrolidinones / pharmacology Case Reports Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Anti-HIV Agents / pharmacology Anti-HIV Agents / therapeutic use Female Genotype HIV Infections / drug therapy HIV Infections / virology HIV Integrase Inhibitors / therapeutic use HIV-1 / enzymology HIV-1 / genetics Humans Middle Aged Mutation Pyrrolidinones / therapeutic use Raltegravir Potassium Viral Load Anti-HIV Agents HIV Integrase Inhibitors Pyrrolidinones Raltegravir Potassium
PMC3150494
21447876
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient
2011